Harrow Health, Inc. (NASDAQ:HROW) Major Shareholder Purchases $641,000.00 in Stock

Harrow Health, Inc. (NASDAQ:HROW) major shareholder Opaleye Management Inc. purchased 50,000 shares of the business’s stock in a transaction on Thursday, March 28th. The shares were bought at an average cost of $12.82 per share, for a total transaction of $641,000.00. Following the completion of the transaction, the insider now directly owns 3,745,600 shares in the company, valued at approximately $48,018,592. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Opaleye Management Inc. also recently made the following trade(s):

• On Wednesday, March 20th, Opaleye Management Inc. purchased 50,600 shares of Harrow Health stock. The shares were bought at an average cost of $9.65 per share, for a total transaction of $488,290.00.

Harrow Health Price Performance

HROW traded up $0.50 during trading on Thursday, reaching $13.23. The company’s stock had a trading volume of 837,654 shares, compared to its average volume of 452,178. The company has a quick ratio of 2.61, a current ratio of 2.83 and a debt-to-equity ratio of 2.60. The firm has a fifty day simple moving average of $10.66 and a two-hundred day simple moving average of $11.59. Harrow Health, Inc. has a 1 year low of $7.60 and a 1 year high of $28.25. The company has a market cap of $467.81 million, a price-to-earnings ratio of -17.65 and a beta of 0.45.

Institutional Trading of Harrow Health

Several institutional investors have recently made changes to their positions in the company. Opaleye Management Inc. increased its holdings in Harrow Health by 0.7% in the 4th quarter. Opaleye Management Inc. now owns 3,820,000 shares of the company’s stock valued at $42,784,000 after purchasing an additional 25,000 shares during the last quarter. Braidwell LP increased its holdings in Harrow Health by 24.5% in the 3rd quarter. Braidwell LP now owns 1,808,684 shares of the company’s stock valued at $25,991,000 after purchasing an additional 356,146 shares during the last quarter. Vanguard Group Inc. increased its holdings in Harrow Health by 2.8% in the 4th quarter. Vanguard Group Inc. now owns 1,808,552 shares of the company’s stock valued at $20,256,000 after purchasing an additional 48,673 shares during the last quarter. BlackRock Inc. increased its holdings in Harrow Health by 261.1% in the 2nd quarter. BlackRock Inc. now owns 1,789,382 shares of the company’s stock valued at $34,070,000 after purchasing an additional 1,293,806 shares during the last quarter. Finally, Morgan Stanley increased its holdings in Harrow Health by 0.5% in the 3rd quarter. Morgan Stanley now owns 1,777,661 shares of the company’s stock valued at $25,545,000 after purchasing an additional 8,364 shares during the last quarter. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Analysts Set New Price Targets

HROW has been the topic of a number of analyst reports. B. Riley dropped their target price on Harrow Health from $30.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, March 22nd. TheStreet cut Harrow Health from a “c-” rating to a “d+” rating in a research report on Tuesday, December 12th.

Harrow Health Company Profile

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.